• 6
  • 1
  • 收藏

Novavax Covid-19 Vaccine Cleared in Australia

Tiger Newspress2022-01-20

Novavax shares rose over 2% premarket as Australia's Therapeutic Goods Administration (TGA) had granted the approval of Novavax Covid-19 vaccine.

Australia's Therapeutic Goods Administration (TGA) has granted the approval for provisional registration of the COVID-19 vaccine developed by Novavax for those aged 18 years and above, the company announced Thursday.

The country will receive the vaccine shipments under the brand name Nuvaxovid.

Last year, Novavax (NVAX) announced an advance purchase agreement (APA) with Australia for 51M doses of the vaccine including an option to deliver additional 10M doses. Serum Institute of India (SII), the world's largest vaccine manufacturer is set to supply the initial doses to Australia.

"The grant of provisional registration of Nuvaxovid by the TGA reflects Novavax's increasing momentum around the globe and represents the first-protein based COVID-19 vaccine authorized for use in Australia," said Novavax (NVAX) CEO Stanley C. Erck.

In December, the company’s COVID-19 vaccine identified as NVX-CoV2373 was cleared by multiple regulatory agencies, including the European Medicines Agency (EMA) and the World Health Organization.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

举报

评论1

  • StansenSG
    ·2022-01-20
    L
    回复
    举报
    收起
 
 
 
 

热议股票

 
 
 
 
 

7x24